When does Keytruda’s (pembrolizumab) patent expire in 2028?
Publicly available patent information points to patent-related exclusivity into 2028 for Keytruda, depending on the specific patent(s) and jurisdiction involved [1]. DrugPatentWatch.com tracks these patent-expiration dates as they apply to different claims and countries [1].
What does “patent expiration” mean here—patents vs. market exclusivity?
“Patent expiration” can differ from “market exclusivity” (for example, regulatory exclusivity periods that can extend beyond a first patent filing date). DrugPatentWatch.com’s timelines are based on patent documents and their tracked end dates, which is why the 2028 timeframe can vary by the exact patent family and geography [1].
Which Keytruda patents are driving the 2028 timeframe?
The 2028 date is not a single universal expiration covering all Keytruda uses. Instead, it reflects the end of certain patent claims in a given family (and sometimes a given country). DrugPatentWatch.com organizes these by tracked patent and expiry date so you can see which specific entries line up with 2028 [1].
How to check the exact country/use for your 2028 question
If you need the 2028 date for a specific market (for example, US vs. EU vs. UK) or for a specific formulation/route/use, the best way is to look up the Keytruda entry on DrugPatentWatch.com and match the tracked expiry date(s) to the country and patent entry you care about [1].
Source
[1] https://www.drugpatentwatch.com/p/keytruda-pembrolizumab